{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:08:09Z","timestamp":1771358889939,"version":"3.50.1"},"reference-count":66,"publisher":"MJH Life Sciences","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a rare, aggressive form of non-Hodgkin lymphoma that arises from cells within the mantle zone (the outer ring of lymphocytes surrounding the center of a lymphatic nodule). Recent treatment advances, such as the introduction of Bruton tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapies, have improved outcomes for many patients. Development of resistance is common, though, and relapse rates are high in MCL. The molecular mechanisms that contribute to resistance remain unclear, and the clinical heterogeneity of MCL can make it difficult to predict how patients will respond to treatment. Thus, there remains an urgent need for continued research on the molecular drivers of MCL pathogenesis, mechanisms of resistance, and novel strategies for targeting these pathways to improve outcomes for patients across the spectrum of disease. In April 2025, researchers gathered for the Lymphoma Research Foundation's 21st Mantle Cell Lymphoma Scientific Consortium and Workshop to discuss recent developments in the characterization and treatment of MCL. This report, which includes a summary of each presentation, aims to review the findings presented at the workshop and highlight new opportunities and unanswered questions in the care of patients with MCL, paving the way for novel treatments to improve outcomes and experiences in the years to come.<\/jats:p>","DOI":"10.46883\/2026.25921063","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:20:05Z","timestamp":1771356005000},"page":"16","source":"Crossref","is-referenced-by-count":0,"title":["2025 Report on the Mantle Cell Lymphoma Scientific Consortium and Workshop Hosted by the Lymphoma Research Foundation"],"prefix":"10.46883","volume":"40","author":[{"given":"Lymphoma Research Foundation","family":"(LRF)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"25947","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.Williams ME, Westermann CD, Swerdlow SH. Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. Blood. Oct 1 1990;76(7):1387-91.","DOI":"10.1182\/blood.V76.7.1387.1387"},{"key":"ref1","unstructured":"2.Dreyling MH, Bullinger L, Ott G, et al. Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma. Cancer Res. Oct 15 1997;57(20):4608-14."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. Jul 1 2017;28(suppl_4):iv62-iv71. doi:10.1093\/annonc\/mdx223","DOI":"10.1093\/annonc\/mdx223"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.Dreyling M, Ferrero S. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? Haematologica. Feb 2016;101(2):104-14. doi:10.3324\/haematol.2014.119115","DOI":"10.3324\/haematol.2014.119115"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. Aug 6 2016;388(10044):565-75. doi:10.1016\/s0140-6736(16)00739-x","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.Zoellner AK, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. Sep 2021;8(9):e648-e657. doi:10.1016\/s2352-3026(21)00195-2","DOI":"10.1016\/S2352-3026(21)00195-2"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. Feb 20 2016;387(10020):770-8. doi:10.1016\/s0140-6736(15)00667-4","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. Mar 2021;35(3):787-795. doi:10.1038\/s41375-020-01013-3","DOI":"10.1038\/s41375-020-01013-3"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.Dreyling M, Doorduijn J, Gin\u00e9 E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. May 25 2024;403(10441):2293-2306. doi:10.1016\/s0140-6736(24)00184-3","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.De Bolos A, Carreras-Caballe M, Sureda-G\u00f3mez M, et al. The SOX11 Interactome Reveals the SOX11:SMARCA4 Complex as a Driver of Oncogenic Transcriptional Programs in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL.","DOI":"10.1182\/blood-2024-200616"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.Ngo VN, Xavier S, Khairnar V, et al. CEACAM1 Orchestrates Lipid Raft Dynamics and B-cell Receptor Signaling in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL.","DOI":"10.21203\/rs.3.rs-5321424\/v1"},{"key":"ref11","unstructured":"12.Marouf A, Mitra S, Isgor I, et al. A Single-Cell Atlas of Classical Mantle Cell Lymphoma Reveals Paired Tumor-Immune Malignant States Correlating with Prognosis. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref12","unstructured":"13.Sharma S, Ali R, Bouska A, et al. Molecular Characterization of TP53-Altered Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref13","unstructured":"14.Singh S, La Ferlita A, Jain N, et al. MALAT1 Long-Non-Coding RNA Regulates SOX11 Expression in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. Oct 27 2021;65(4):625-639. doi:10.1042\/ebc20200032","DOI":"10.1042\/EBC20200032"},{"key":"ref15","unstructured":"16.Gao J, Zhao X, Yin Q, et al. Combinatorial Therapy of MCL-1i with CAR-T to Overcome Therapy Resistance and Reciprocally Enhance Treatment Efficacies Against Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.Yuan R, Wang MY, Bi C, Zhao X, Tao J. MCL1 as a therapeutic vulnerability in Burkitt lymphoma. Leukemia. Apr 2023;37(4):934-937. doi:10.1038\/s41375-023-01827-x","DOI":"10.1038\/s41375-023-01827-x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.Wang MY, Li T, Ren Y, et al. MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas. Blood Cancer J. Jan 14 2021;11(1):14. doi:10.1038\/s41408-020-00402-2","DOI":"10.1038\/s41408-020-00402-2"},{"key":"ref18","unstructured":"19.Yin Q, Gao J, Whitaker S, et al. CD24 CAR-T and Bispecific Antibody (BsAb) As A Next Generation of Immunotherapy of Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. Aug 2019;572(7769):392-396. doi:10.1038\/s41586-019-1456-0","DOI":"10.1038\/s41586-019-1456-0"},{"key":"ref20","unstructured":"21.Rink JS, Lin AY, Thaxton S, Gordon LI. Reduction of Glutathione Peroxidase 4 by High-Density Lipoprotein-Like Nanoparticles (Au-HDL NPs) Potently Induces Cell Death in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref21","unstructured":"22.Alinari L, Barta B, Abusaleh K, et al. CD74 CAR-T Cells Target Mantle Cell Lymphoma and Its Immunosuppressive Microenvironment. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref22","unstructured":"23.Basappa J, Wang S, Lobello C, et al. Inosine Monophosphate Dehydrogenase-2 (IMPDH2) Is a Novel Therapeutic Target in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref23","unstructured":"24.Morsy MHA, Lilienthal I, Amador V, et al. SOX11 Enhances Sensitivity to Cytarabine and DNA-Damaging Agents by Impairing SAMHD1 Activity. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.Nordstr\u00f6m L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br J Haematol. Jul 2014;166(1):98-108. doi:10.1111\/bjh.12854","DOI":"10.1111\/bjh.12854"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. Jan 25 2018;131(4):417-420. doi:10.1182\/blood-2017-07-797019","DOI":"10.1182\/blood-2017-07-797019"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.Abdelrazak Morsy MH, Lilienthal I, Lord M, et al. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma. Blood. May 9 2024;143(19):1953-1964. doi:10.1182\/blood.2023022241","DOI":"10.1182\/blood.2023022241"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.Hwang SY, Chen-Kiang S, Gibbin C, Martin P, Paik J. Leveraging SMARCA4 Dependency of Mantle Cell Lymphomas to Overcome BTK Inhibitor Resistance. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL.","DOI":"10.1182\/blood-2024-212104"},{"key":"ref28","unstructured":"29.Chen A, Vuong D, Rodriguez-Rodriguez S, Roleder C, Phillips T, Danilov AV. Cyclin-Dependent Kinase 5 (CDK5) Contributes to Bruton Tyrosine Kinase Inhibitor (BTKi) Resistance via IRE1\u03b1\/Xbp1s Axis in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref29","unstructured":"30.Qiu K, Gao J, Yin Q, et al. Multi-Omics Analyses Delineates Mechanisms of Resistance to Ibrutinib-Venetoclax Combination Therapy in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref30","unstructured":"31.Lobello C, Wang S, Rushmore D, Dupoux V, Nath K, Wasik MA. Unlocking the Potential of CAR-T-Cell Immunotherapy Targeting ROR1 in Combination with EZH2 Inhibition in Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.Sarkozy C, Chartier L, Ribrag V, et al. Validation of POD24 as a Robust Early Clinical Indicator of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials, a LYSA Study. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL.","DOI":"10.1038\/s41408-025-01241-9"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.Sarkozy C, Chartier L, Ribrag V, et al. Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. Blood Cancer J. Apr 24 2025;15(1):78. doi:10.1038\/s41408-025-01241-9","DOI":"10.1038\/s41408-025-01241-9"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.Aymard M, Cheminant M, Houot R, et al. Outcome of pts with Mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL.","DOI":"10.1182\/bloodadvances.2025017234"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.Aymard M, Cheminant M, Houot R, et al. Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group. Blood Adv. Jan 13 2026;10(1):75-82. doi:10.1182\/bloodadvances.2025017234","DOI":"10.1182\/bloodadvances.2025017234"},{"key":"ref35","unstructured":"36.Wang J, Zhou J, Wang Y, et al. Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.Ong SY, Chen Y, Tan MSY, Ho AYL, Hwang WYK, Lim F. Current perspectives on resistance to chimeric antigen receptor T-cell therapy and strategies to improve efficacy in B-cell lymphoma. Eur J Haematol. Feb 2024;112(2):144-152. doi:10.1111\/ejh.13964","DOI":"10.1111\/ejh.13964"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov. Dec 2023;22(12):976-995. doi:10.1038\/s41573-023-00807-1","DOI":"10.1038\/s41573-023-00807-1"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.Jain P, Nastoupil L, Westin J, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. Jan 2021;192(2):e38-e42. doi:10.1111\/bjh.17197","DOI":"10.1111\/bjh.17197"},{"key":"ref39","unstructured":"40.Melani C, Lakhotia R, Pittaluga S, et al. Phase 1b\/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed\/Refractory (R\/R) and Treatment-Na\u00efve (TN) Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease (MRD). Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.Melani C, Lakhotia R, Pittaluga S, et al. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. N Engl J Med. Jun 20 2024;390(23):2143-2155. doi:10.1056\/NEJMoa2401532","DOI":"10.1056\/NEJMoa2401532"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.Melani C, Lakhotia R, Pittaluga S, et al. Multi-targeted therapy with ViPOR in mantle cell lymphoma (MCL); Updated analysis of efficacy and minimal residual disease (MRD). Hematol Oncol. 2025;43(S3)(supp):e45_70093.","DOI":"10.1002\/hon.70093_45"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.Ruan J, Bond D, Shah B, et al. MRD Analysis in Phase 2 Trial of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) for Patients with Treatment-Na\u00efve Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL.","DOI":"10.1182\/blood-2024-204495"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.Lopedote P, Shouse G, Siddiqi T, Phillips T, Danilov A. A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL.","DOI":"10.1080\/10428194.2025.2566316"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. Oct 2012;122(10):3416-23. doi:10.1172\/jci61272","DOI":"10.1172\/JCI61272"},{"key":"ref45","unstructured":"46.Wang Y, Larson MC, Hwang SR, et al. Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line (1L) Bendamustine-Rituximab (BR) and Second- line (2L) Bruton\u2019s Tyrosine Kinase Inhibitor (BTKi) Therapy. Presented at the Mantle Cell Lymphoma Scientific Workshop; April 29-30, 2025; Chicago, IL."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. Jun 30 2022;386(26):2482-2494. doi:10.1056\/NEJMoa2201817","DOI":"10.1056\/NEJMoa2201817"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.Wang M, Salek D, Belada D, et al. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. Jul 10 2025;43(20):2276-2284. doi:10.1200\/jco-25-00690","DOI":"10.1200\/JCO-25-00690"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.Kumar A, Soumerai J, Abramson JS, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. Jan 30 2025;145(5):497-507. doi:10.1182\/blood.2024025563","DOI":"10.1182\/blood.2024025563"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.Phillips TJ, Bond D, Takiar R, et al. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Adv. Aug 22 2023;7(16):4518-4527. doi:10.1182\/bloodadvances.2023009992","DOI":"10.1182\/bloodadvances.2023009992"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. Apr 2 2020;382(14):1331-1342. doi:10.1056\/NEJMoa1914347","DOI":"10.1056\/NEJMoa1914347"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. Jan 20 2023;41(3):555-567. doi:10.1200\/jco.21.02370","DOI":"10.1200\/JCO.21.02370"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.Zhang S, Jiang VC, Han G, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. May 17 2021;12(1):2877. doi:10.1038\/s41467-021-22872-z","DOI":"10.1038\/s41467-021-22872-z"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.Jiang VC, Liu Y, Lian J, et al. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J Clin Invest. Feb 1 2023;133(3)doi:10.1172\/jci165694","DOI":"10.1172\/JCI165694"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.Zhao X, Bodo J, Sun D, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. Mar 2015;168(5):765-8. doi:10.1111\/bjh.13149","DOI":"10.1111\/bjh.13149"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.Agarwal R, Chan YC, Tam CS, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. Jan 2019;25(1):119-129. doi:10.1038\/s41591-018-0243-z","DOI":"10.1038\/s41591-018-0243-z"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.Liu T, Lam V, Thieme E, et al. Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner. Clin Cancer Res. Sep 1 2021;27(17):4910-4922. doi:10.1158\/1078-0432.Ccr-21-0464","DOI":"10.1158\/1078-0432.CCR-21-0464"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.Galimberti S, Genuardi E, Mazziotta F, et al. The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. Front Oncol. 2019;9:528. doi:10.3389\/fonc.2019.00528","DOI":"10.3389\/fonc.2019.00528"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. Dec 2021;39(12):1537-1547. doi:10.1038\/s41587-021-00981-w","DOI":"10.1038\/s41587-021-00981-w"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. May 2015;16(5):541-9. doi:10.1016\/s1470-2045(15)70106-3","DOI":"10.1016\/S1470-2045(15)70106-3"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.Kurtz DM, Scherer F, Jin MC, et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. Oct 1 2018;36(28):2845-2853. doi:10.1200\/jco.2018.78.5246","DOI":"10.1200\/JCO.2018.78.5246"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.Lakhotia R, Melani C, Dunleavy K, et al. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv. Apr 26 2022;6(8):2667-2680. doi:10.1182\/bloodadvances.2021006397","DOI":"10.1182\/bloodadvances.2021006397"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.Lewis DJ, Jerkeman M, Sorrell L, et al. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial. Lancet. Oct 25 2025;406(10514):1953-1968. doi:10.1016\/s0140-6736(25)01432-1","DOI":"10.1016\/S0140-6736(25)01432-1"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.Le Gouill S, de Wilde V, Eyre TA, et al. Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial. Blood. 2024;144(supp 1):745.","DOI":"10.1182\/blood-2024-194357"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.Wagner-Johnston N, Jegede O, Spurgeon SE, et al. Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients \u2264 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181. Blood. 2024;144(supp 1):236.","DOI":"10.1182\/blood-2024-194641"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.Fenske TS, Wang XV, Till BG, et al. Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial. Blood. 2024;144(supp 2):LBA-6.","DOI":"10.1182\/blood-2024-212973"}],"container-title":["ONCOLOGY"],"original-title":[],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:20:10Z","timestamp":1771356010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/2025-report-on-the-mantle-cell-lymphoma-scientific-consortium-and-workshop-hosted-by-the-lymphoma-research-foundation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.46883\/2026.25921063","relation":{},"ISSN":["0890-9091","2767-7389"],"issn-type":[{"value":"0890-9091","type":"print"},{"value":"2767-7389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}